CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
This study will evaluate the efficacy and safety of different doses of EVO756 in adults with moderate to severe atopic dermatitis.
Phase 2
Fremont, California, United States of America and 16 other locations
The primary objective of the study is to assess the long-term safety of dupilumab in pediatric participants with AD.The secondary objectives of the s...
Phase 3
Palo Alto, California, United States and 83 other locations
The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic der...
Phase 2
Lafayette, California, United States of America and 98 other locations
B7451015 is a Phase 3 study to evaluate Abrocitinib with or without Topical Medications in patients aged 12 years and older who have moderate to seve...
Phase 3
San Francisco, California, United States and 541 other locations
Safety, tolerability, and preliminary efficacy of soquelitinib in participants with moderate to severe AD
Phase 1
Palo Alto, California, United States and 15 other locations
The primary objective of this study is to describe the long-term safety and tolerability of rocatinlimab in participants with moderate-to-severe AD.
Phase 3
San Francisco, California, United States and 555 other locations
The goal of this clinical trial is to learn if CGB-500 works to treat atopic dermatitis in participants ages 12 and older. The goal is also to learn...
Phase 2
Fremont, California, United States of America and 16 other locations
Period 2, participants that completed Period 1 will either remain on their assigned dose or be reassigned to a different dose based on their Eczema...
Phase 3
Redwood City, California, United States and 97 other locations
The objective of this study is to assess the efficacy and safety of upadacitinib combined with topical corticosteroids (TCS) for the treatment of ado...
Phase 3
Stanford, California, United States and 193 other locations
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Phase 3
San Francisco, California, United States and 342 other locations
Clinical trials
Research sites
Resources
Legal